Member Info for StephenFryUp

Thanks to Trench for pointing this out, a real possibility i reckon, and not surprising given the niche market.

Its there as a black trade.

Nice buy there.

Hence a perfect time to buy for me. Let's see where it is at year end. Obviously i believe much higher than now, but let's see. I'm more than happy buying at this price.

How does that make sense ?? Why would it lead to speculate more bad news is on the horizon ??

This is from the latest RNS..

"Since the completion of the refinancing, we are encouraged to have added 128 new leads to a growing pool of opportunities which gives management confidence that significant orders will be signed before the 2023 calendar year end."

So they are confident of signing significant orders by the end of the year, which is only a few weeks away !!

You missed these bits off.....

"However, with revised strategy set out by the new management team gaining traction with a focus on building and converting the pipeline, we are completely focused on converting those opportunities and on achieving market expectations for the full year.

Under the new management team, and with cash on the balance sheet, we have seen a significant improvement in customer confidence. The pipeline of opportunities that are at advanced stages of discussion currently stands at a healthy £3.3 million across 28 unique projects (subject to commercial and scientific attrition). Since the completion of the refinancing, we are encouraged to have added 128 new leads to a growing pool of opportunities which gives management confidence that significant orders will be signed before the 2023 calendar year end.

Executive Chairman Steve Hull commented: "I am inspired by how much progress we have made in such a short time under new management. We appreciate the support of our staff, customers and shareholders who are invaluable to us turning the business around. We are encouraged by the response from customers since the Company refinanced and we have confidence that the team will be able to convert a number of existing pipeline opportunities, in addition to attracting a complement of new customers, to meet market expectations for the full year."

I personally like the word "Significant", hence I am a buyer at these levels..

Eagles !

Why do you care ?

Before anyone starts, it's not advice or a ramp, it's how i see things at this moment in time.

£2.5mln market cap with c.£800,000 cash

5 new contracts plus recommenced Merck revenues (€500,000 annually)

Hired 3 new personal to drive the business forward

Main points from the annual report below :

The Company is looking forward to a successful financial year 2024 during which it aims to achieve a new best ever level of total income, generated from its current core business and emerging biostatistics consulting offering.

Device to measure blood counts

Feedback from clinicians suggests that enabling patients to undergo these diagnostic tests in a primary care or home setting would facilitate use of our tool and as such we are actively exploring opportunities to work with Beyond Blood.

Collaborations

we are open to and continue to explore other approaches including risk sharing and collaboration. An example of this includes the risk-sharing deal with ValiRx plc announced in February 2021 for which terms have been fully disclosed and which would be triggered by the receipt by ValiRx of licensing revenues related to VAL-201

Strategic aims

expand and diversify core consulting business both through repeat business and through the acquisition of new clients;

· Supplement consulting revenues through grant funded projects, especially in the field of personalised medicine (CRUK, Innovate UK, NIHR etc);

· Expand business into related fields, starting with biostatistics. This will be the subject of further announcements later this calendar year;

· Develop new, complementary areas of business such as personalised medicine and other service offerings in drug discovery and development that can add long term value to the business.

Big delayed sell there, and explains last week's price movements, would have taken a few days to fill. Probably a distressed pi, but whoever it is, we are now free to move up again

Out of interest why did you buy in ? You gave your reasons for selling down to 20k shares, and totally respect that, just wondered what changed again for you to buy back so quickly ?

More than welcome mate.

Exactly this, thanks Laura, I had never mentioned it was in an RNS

Before anyone starts, it's not advice or a ramp, it's how i see things at this moment in time.

£2.5mln market cap with c.£800,000 cash

5 new contracts plus recommenced Merck revenues (€500,000 annually)

Hired 3 new personal to drive the business forward

Main points from the annual report below :

The Company is looking forward to a successful financial year 2024 during which it aims to achieve a new best ever level of total income, generated from its current core business and emerging biostatistics consulting offering.

Device to measure blood counts

Feedback from clinicians suggests that enabling patients to undergo these diagnostic tests in a primary care or home setting would facilitate use of our tool and as such we are actively exploring opportunities to work with Beyond Blood.

Collaborations

we are open to and continue to explore other approaches including risk sharing and collaboration. An example of this includes the risk-sharing deal with ValiRx plc announced in February 2021 for which terms have been fully disclosed and which would be triggered by the receipt by ValiRx of licensing revenues related to VAL-201

Strategic aims

expand and diversify core consulting business both through repeat business and through the acquisition of new clients;

· Supplement consulting revenues through grant funded projects, especially in the field of personalised medicine (CRUK, Innovate UK, NIHR etc);

· Expand business into related fields, starting with biostatistics. This will be the subject of further announcements later this calendar year;

· Develop new, complementary areas of business such as personalised medicine and other service offerings in drug discovery and development that can add long term value to the business.

Agree mate.. Ive got plenty of time to listen to both sides, but not when some become personal and malicious... I just ignore now, its much nicer that way.. Its clear the company until recently hasnt done as us long term holders expected, but that doesnt mean we arent in a good place going forward..

As far as I was aware from reading RNS's we had plenty of cash before the raise, and post raise must not have £800k plus...

Is my buy showing as a sell

Thats not true... I was getting 2.65 to buy in to close.

Buy is the biggest individual buy I have seen in my time here.... Follow the money...

As I said, well done, great to hear you are smashing it, long may it continue.